NHS Branded Medicines Tranche Framework for London and South of England
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 S...
Buyer
NHS England
Value
£380,950,720
Published
20 Aug 2024
Closes
5 Apr 2024
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Open
Category
Goods
Contract starts
31 Aug 2024
Contract ends
31 Aug 2026
CPV classifications
33600000
Pharmaceutical products
Lots
Lot default NHS Branded Medicines Tranche Framework for London and South of England
£380,950,720
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a perio...
Delivery: East Midlands · United Kingdom, East of England · United Kingdom, London · United Kingdom, North East · United Kingdom, North West · United Kingdom, South East · United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
20 Aug 2024
Awarded contract notice on Contracts Finder
Award notice · Web page
Transparency Award Schedules - London & South of England - CM_PHR_225689_02
Not provided
Transparency Award Schedules - London & South of England - CM_PHR_225689_02
Transparency Award Schedules - London & South of England - CM_PHR_225689_01
Not provided
Transparency Award Schedules - London & South of England - CM_PHR_225689_01
Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03
Not provided
Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03
Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024
Not provided
Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024
Word document
Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024
Not provided
Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024
Contains public sector information licensed under the Open Government Licence v3.0.